Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

No, I don’t believe in government angels or gene-editing angels.

Somatic gene therapies, which involve modifying a patient's DNA to treat or cure a disease, have been successfully used to address HIV, sickle-cell disease and transthyretin amyloidosis. The technique could also vastly improve treatment for a variety of cancers. Jul 12, 2021 ~ who.int

https://rumble.com/vwxob3-joe-allen-in-studio-talks-gene-editing-and-biolabs-in-ukraine.html

Let ZYESAMI/AVIPTADIL/RLF-100 handle health conditions, now!

Treatment with an inhaled formulation of synthetic vasoactive intestinal peptide (Aviptadil, Bachem) was initiated, at a dose of 70 µg three times daily, as an alternative treatment to avoid glucocorticoid-related side effects and systemic immunosuppression. Vasoactive intestinal peptide has been shown to dampen type 1 helper T cell (Th1) responses by inhibiting effector T cells and boosting regulatory T cells through its G-protein–coupled receptors (VPAC1 and VPAC2). Its inhaled application in sarcoidosis increases alveolar regulatory T cells and reduces proinflammatory cytokines, resulting in clinical improvement.4

Treatment with inhaled vasoactive intestinal peptide resulted in clinical and radiologic improvement in the lungs (Figure 1B). Analysis of BAL fluid showed reduced alveolar lymphocytosis with reduced CD28 expression and increased regulatory T cells. Spontaneous and lipopolysaccharide-induced release of tumor necrosis factor, reflecting the inflammatory alveolar milieu, were dampened during treatment. Vasoactive intestinal peptide was not associated with toxic effects and did not influence lymphocyte subtypes in peripheral blood (Table S1). Eight weeks after cessation of the treatment, the patient had systemic nonpulmonary progression of melanoma disease.

Our findings support inhaled vasoactive intestinal peptide as a local therapy to reduce the alveolar inflammation found in patients with immune checkpoint inhibitor pneumonitis. Whether this therapy has an influence on tumor progression cannot be determined on the basis of this case. However, further studies are indicated to investigate whether vasoactive intestinal peptide may be a therapeutic option for immune checkpoint inhibitor pneumonitis.

https://www.nejm.org/doi/full/10.1056/NEJMc2000343

Dr. Cadegiani noted that “to date, there is no other molecule capable of working at late stage against COVID-19, and at the same not causing immunosuppression.”

He also believes aviptadil blocks the IL-6, the most dangerous cytokine at the center of the pulmonary dysfunction related to COVID-19. “The importance is that IL-6 is the cytokine that is not effectively blocked by glucocorticoids, even in very high doses. Thus, aviptadil/VIP could confer additional protection when we most need and when we have the fewest resources for.”

He went further to suggest that it is downright malpractice for hospitals not to try this drug at late stage, given the absence of alternatives. “Due to the absence of therapeutic alternatives targeting AT-2 and IL-6, and given the already well-established safety profile, its approval goes beyond the attempt-to-try principle, since it is highly plausible and likely that it works. Therefore, instead of an action of attempt-to-try when giving aviptadil, not providing it when patients fail to respond to other therapies can be considered a medical negligence, from a bioethical perspective.”

https://amgreatness.com/2022/03/09/in-letter-to-fda-and-niaid-ron-johnson-demands-to-know-why-promising-late-stage-covid-drug-was-never-approved/